Virtual vs in-person follow-up visits after radiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study compares virtual (telehealth) and in-person on-treatment follow-up visits in a high-volume radiation oncology center to assess logistical feasibility and satisfaction. Structured surveys will measure patient and physician experiences, communication quality, and perceived clinical utility of telehealth during active cancer treatment. The evaluation considers implementation aspects, accessibility, and acceptability of telemedicine as a care modality in this setting. The study reflects on evolving telehealth use in the post-COVID era and its potential to reduce travel burdens and missed appointments for cancer patients. No interventional treatment changes are described.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients who are 18 years and above.
2. All patients who are undergoing radiotherapy (\>5 fractions).
3. Capacity to provide informed consent for participation in the study.

Exclusion Criteria:

1. Patients below 18 years
2. Unable to provide informed consent for participation in the study.

Where it's running

• Shaukat Khanum Memorial Cancer hospital & Research Centre
  Lahore, Punjab Province, Pakistan Recruiting

Study contacts

• Study coordinator: Anusha Haider, MBBS
• Email: anushahaider@skm.org.pk
• Phone: 03244534247

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Analysis of outcomes and side effects in patients receiving radiation therapy

  This study looks at the results and side effects of radiation therapy in patients at Winterthur Cantonal Hospital to see how treatment can be improved for future patients.

  Recruiting Kantonsspital Winterthur KSW · Winterthur, Canton of Zurich · NCT05192876

• Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread

  This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07893392

• Tributyrin as a dietary supplement to help prevent radiation-induced rectal injury during rectal cancer chemoradiation

  This study tests whether adding tributyrin to standard chemoradiotherapy helps prevent acute radiation-induced rectal injury in people with locally advanced rectal cancer.

  Recruiting Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07802002

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in Localized Rectal Cancer

  In people with locally advanced, treatment-naive rectal cancer, this study tests whether adding two immunotherapy drugs to a standard chemotherapy after short-course radiotherapy can improve tumor response.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07686640

• Different-Dose Short-Course Radiotherapy With CAPOX, PD-1 Blockade, and IL-2 in Locally Advanced Rectal Cancer

  This phase II trial tests whether a low-dose short-course radiotherapy combined with CAPOX, a PD-1 blocker, and IL-2 works as well as the standard-dose short-course approach in patients with locally advanced rectal cancer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07646639

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.